IL6 and cyclic hematopoiesis: In a study including a large cohort of CHIP carriers, TET2 mutations in blood cells were associated with markedly increased serum levels of IL-1β and IL-6 (interleukin 6) [54], implicating pro-inflammatory cytokines as causal factors in CVD progression connected with TET2-induced CH.